Alimera Sciences, Inc. (NASDAQ:ALIM – Free Report) – HC Wainwright cut their Q3 2024 earnings per share estimates for shares of Alimera Sciences in a report issued on Thursday, May 16th. HC Wainwright analyst Y. Chen now anticipates that the biopharmaceutical company will earn ($0.01) per share for the quarter, down from their prior forecast […]
StockNews.com downgraded shares of Alimera Sciences (NASDAQ:ALIM – Free Report) from a buy rating to a hold rating in a research note issued to investors on Tuesday morning. Separately, Maxim Group started coverage on shares of Alimera Sciences in a research report on Monday, March 25th. They set a buy rating and a $10.00 price […]
Alimera Sciences (NASDAQ:ALIM – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Monday. Separately, Maxim Group initiated coverage on shares of Alimera Sciences in a report on Monday, March 25th. They set a “buy” rating and a $10.00 […]
StockNews.com began coverage on shares of Alimera Sciences (NASDAQ:ALIM – Free Report) in a research report report published on Saturday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Separately, HC Wainwright reissued a buy rating and issued a $5.00 price objective on shares of Alimera Sciences in a research note on […]
StockNews.com initiated coverage on shares of Alimera Sciences (NASDAQ:ALIM – Free Report) in a research note published on Wednesday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Separately, HC Wainwright reissued a buy rating and set a $5.00 target price on shares of Alimera Sciences in a research note on Monday, […]